Literature DB >> 1551992

Evaluation of the Genetic Systems Corp. Integra HIV-1 Pageblot system.

C A Starkey1, B Yen-Lieberman, M R Proffitt.   

Abstract

The Genetic Systems Corp. Integra HIV-1 Pageblot system was evaluated as a supplementary assay to confirm the presence of antibodies to human immunodeficiency virus type 1 in 57 specimens from individuals at high risk of infection with the virus. Forty-one specimens identified as reactive in the Genetic Systems Integra HIV-1 Pageblot system were likewise identified as reactive in a U.S. Food and Drug Administration-licensed (Biotech/Dupont) Western blot (immunoblot). Six specimens identified as indeterminate in either or both immunoblot assays were all identified as nonreactive in a U.S. Food and Drug Administration-licensed enzyme immunoassay with recombinant antigens.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1551992      PMCID： PMC265142          DOI： 10.1128/jcm.30.3.726-728.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Frequency of indeterminate western blot tests in healthy adults at low risk for human immunodeficiency virus infection. The NIAID AIDS Vaccine Clinical Trails Network.

Authors:  K Midthun; L Garrison; M L Clements; H Farzadegan; B Fernie; T Quinn
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  Evaluation of blood collected on filter paper for detection of antibodies to human immunodeficiency virus type 1.

Authors:  P Fortes; J Menitove; A Ross; R Steece; K Cabrian; C Ferrera; P A Perkins; J Sturge; R Lealos; M S Krieger
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

3.  False-positive autoantibodies in HIV infection.

Authors:  A Davenport; P J Grant
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

4.  What do western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors?

Authors:  J Genesca; J W Shih; B W Jett; I K Hewlett; J S Epstein; H J Alter
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

5.  Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III.

Authors:  L E Henderson; R Sowder; T D Copeland; S Oroszlan; L O Arthur; W G Robey; P J Fischinger
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

6.  The thymus in acquired immune deficiency syndrome. Comparison with other types of immunodeficiency diseases, and presence of components of human immunodeficiency virus type 1.

Authors:  H J Schuurman; W J Krone; R Broekhuizen; J van Baarlen; P van Veen; A L Golstein; J Huber; J Goudsmit
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

7.  HLA antibodies as a cause of false-positive reactions in screening enzyme immunoassays for antibodies to human T-lymphotropic virus type III.

Authors:  M H Sayers; P G Beatty; J A Hansen
Journal:  Transfusion       Date:  1986 Jan-Feb       Impact factor: 3.157

Review 8.  Human immunodeficiency virus test evaluation, performance, and use. Proposals to make good tests better.

Authors:  J S Schwartz; P E Dans; B P Kinosian
Journal:  JAMA       Date:  1988-05-06       Impact factor: 56.272

9.  Differences in human immunodeficiency virus type 1 (HIV-1) anti-p24 reactivities in serum of HIV-1-infected and uninfected subjects: analysis of indeterminate western blot reactions.

Authors:  J Povolotsky; J W Gold; N Chein; P Baron; D Armstrong
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

10.  Sequence similarities between human immunodeficiency virus gp41 and paramyxovirus fusion proteins.

Authors:  F Gonzalez-Scarano; M N Waxham; A M Ross; J A Hoxie
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.